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 The architecture of inherited genetic susceptibility to cancer is defined by a spectrum of 
predisposition alleles which have differing frequency and impact. 
 Genome-wide association studies (GWAS) provide an agnostic approach to identify genetic 
variation influencing cancer risk. GWAS of most cancers have been performed and 
hundreds of risk alleles have been identified, most of which are common and individually 
confer a modest increase in risk. 
 Most cancer risk loci identified through GWAS locate to non-coding regions of the genome 
and influence gene expression through diverse mechanisms. 
 As well as improving our understanding of cancer, information from  GWAS  has  direct 
clinical relevance in identifying non-genetic aetiological risk factors, optimising population 
screening, identifying therapeutic targets, drug repositioning and prognostication. 
 Although challenging, deciphering the biological basis of associations is necessary to fully 
realise the potential of GWAS. 
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Genome-wide association studies (GWAS) provide an agnostic approach for investigating the 
genetic basis of complex diseases. In oncology, GWAS of nearly all common malignancies have 
been performed and over 700 genetic variants associated with increased risks identified. As well 
as revealing novel pathways important in carcinogenesis, these studies have shown that 
common genetic variation contributes significantly to the heritable risk of many common 
cancers. The clinical application of GWAS is starting to provide opportunities for drug discovery 
and repositioning, as well as cancer prevention. Deciphering the functional and biological basis 
of associations is, however challenging and is in part a barrier to fully unlock the potential of 
GWAS. 
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Epidemiological studies provide strong support for a hereditary component to the aetiology of 
common cancers1. Many cancers show a higher concordance in monozygotic twins as compared 
with dizygotic twins or siblings2. While this concordance is compatible with inherited genetic 
variation rather than lifestyle or environmental risk factors, it does not exclude non-genetic 
mechanisms as a basis of apparent heritability [G]. For example, the high concordance of acute 
leukaemia in monozygotic twins has an in utero explanation3. The pattern of relative risk (RR) [G] 
for most common cancers is that familial RRs are greatest in relatives of early-onset  cancer 
patients, which is compatible with tumours developing in these genetically susceptible individuals 
at an earlier age4. For most common cancers, risks in first-degree relatives of patients are 
increased two- to three-fold for the same cancer. Notable exceptions are chronic lymphocytic 
leukaemia, and thyroid and testicular cancers, for which risks are increased four- to eight-fold1. 
The genetic architecture underscoring these familial risks is now known to reflect a range of alleles 
with varying frequencies and impact. 
 
More than 40 years ago, Anderson stated that the two- to three-fold excess risks of cancer seen in 
first-degree relatives of cancer patients, “are not indicative of a strong genetic effect. They are 
more suggestive of a polygenic mechanism, i.e. the involvement of many genes with small effects 
acting in concert with environmental or non-genetic factors with larger and more important 
effects”5. This conclusion is incorrect, as the RRs in relatives of patients compared with the 
population will usually be more than one order of magnitude lower than the RRs in susceptible 
compared with non-susceptible individuals. The observed RRs are diluted by three factors. Firstly, 
not  all  cancer  patients  are  susceptible.  Secondly,  even  fewer  of  the  relatives  are  susceptible. 
Thirdly, the general population is composed of both susceptible and non-susceptible individuals. 
However, such modest excess familial risks are entirely compatible with Mendelian predisposition 
[G], provided that the genetic effect is substantial4. Indeed genetic linkage and positional cloning 
studies performed in the 1980s and 1990s led to the  identification  of  many  high  penetrance 
cancer susceptibility genes (CSGs) [G], for example those for breast and ovarian cancers (BRCA1 
and BRCA2)6-8, colorectal cancer (CRC; APC and the mismatch repair (MMR) genes MLH1 and MSH29-
13) and melanoma CDKN2A)14,15 within certain families. 
To date mutations in more than 70 CSGs associated with high-penetrance [G] cancer susceptibility 
syndromes have been identified, which confer RRs of 5-10016  (Fig. 1). However, these syndromes 




only account for a small fraction of the familial risks of the respective cancers, leaving much of the 
heritability unexplained. For example, high-penetrance mutations are responsible for most breast 
cancer and CRC patients in families with more than three patients (i.e. indicative of Mendelian 
inheritance), but are responsible for only a minority of those with two patients17-19. Mutations in 
known predisposition genes, including BRCA1 and BRCA2, account for less than 25% of the two- 
fold excess risk in the relatives of patients with breast cancer18,20. Similarly, more than 60% of the 
excess familial risk of CRC remains unaccounted for19,21. 
 
Over the past 20 years, extensive efforts to discover additional, high-penetrance CSGs for breast 
cancer and CRC have been made but no gene with a similar profile to BRCA1, BRCA2 or the MMR 
genes has been identified. If additional CSGs exist, as is the case in CRC with POLE22 and NTHL123 
variants, each will account for only a small proportion of the familial risk (i.e. <1%)19. These data, 
coupled with the previously described high estimates of cancer heritability from twin  studies, 
suggest that much of the missing heritability will be polygenic. Here, the co-inheritance of genetic 
variants, each of which has a modest individual effect, can cause a wide range of risk in the 
population. 
 
Paradoxically therefore, while the reasoning behind Anderson's statement was incorrect, it is now 
recognized that much of the genetic architecture of cancer susceptibility is in fact explained by 
polygenic inheritance. Thus, a high proportion of cancers may arise in a genetically susceptible 
minority of individuals in a population - a consequence of the combined effects of common low- 
penetrance alleles and rare disease-causing variants that confer moderate cancer risks. In 
appreciation of this, the past decade has seen a shift in gene discovery efforts from models of 
predisposition based on high-penetrance single-gene mutations (i.e. causative of  cancer 
syndromes) to multi-genic models. This Review focuses on the  major findings  from association 
studies, in particular genome-wide association studies (GWAS), both in terms of understanding the 
allelic architecture of cancer susceptibility and its functional basis as well as ongoing challenges 
and future perspectives. 
 
[H1] The advent of GWAS 
Association studies have detected two main classes of cancer susceptibility variants with different 
levels of risk and prevalence in the population. Firstly, rare moderate-penetrance variants (risk 
allele  frequency  [G]  <2%;  odds  ratios  (ORs)  [G]  >2.0)  have  been  identified  through  the  direct 




interrogation of candidate genes. For example, other genes encoding proteins involved in the DNA-
damage response pathway, in addition to BRCA1 and BRCA2, such as ATM24,25, CHEK226 and 
PALB227,28, have been associated with an increased breast cancer risk. Based on their risk allele 
frequencies of 0.1% to 0.5% and the modest two-fold increase in risk associated with  each, 
variation in these genes contribute little to the familial risk of breast cancer. Secondly, common 
low-penetrance alleles (risk allele frequency >5%; OR <1.5) have been identified by GWAS. It is 
likely however that the spectrum of penetrance and frequency of risk alleles for many cancers 
occurs on a continuum. This dichotomy probably reflects the subgroups of risk alleles that are 
most readily detected, rather than the underlying biological or evolutionary constraints. 
 
GWAS were made possible by improved insight into common genetic variation coupled with 
technological developments in high-throughput genotyping. Through an agnostic genome-based 
approach, GWAS compares the frequency of common DNA variations in a large series of unrelated 
cancer patients and matched healthy individuals (referred to as ‘controls’ from hereon), to identify 
genetic variants associated with cancer risk (Fig. 2). GWAS of most of the common cancers have 
now been performed and genomic variants associated with their risks identified, providing direct 
evidence of polygenic susceptibility. 
 
[H1] Study design for GWAS 
From 2006 onwards, knowledge of single nucleotide polymorphisms (SNPs, the most  common 
genetic variant) gained from the Human Genome Project29,30 and the International Hap Map 
Project31, together with technical advances in high-throughput genotyping technology made large- 
scale GWAS a viable option. 
 
The underlying basis of GWAS is that adjacent stretches of DNA tend to be non-independently co- 
inherited. This non-random association of alleles (linkage disequilibrium (LD) [G]) allows certain 
SNPs to act as proxies, or tagSNPs, for adjacent SNPs32. Therefore, the number of SNPs that need 
to be genotyped to capture most common variants (i.e. minor allele frequency >5%) is reduced to 
around 300,00033. By determining which SNP alleles occur more or less frequently in patients 
compared with healthy individuals, genomic regions associated with risk can be identified (Fig. 2). 
 
There is a general need for patients and controls to be appropriately matched. This matching is to 
ensure adequate statistical power, and to minimise biases or confounding factors leading to false- 




positive associations. For example, methods have been developed that can correct for potential 
population differences between patients and controls34. To mitigate the issue of multiple 
comparisons and reduce false-positive associations, stringent statistical thresholds are necessary. 
The Bonferroni correction is commonly applied, whereby a P-value of 5.0x10-8 corresponds to 
genome-wide significance at the 5% threshold (i.e. 0.05/1,000,000 SNPs) [BOX 1]. The strength of 
associations, however, have to be interpreted with caution owing to the “winner's curse”. 
Thereby, an overestimation of effect size [G] is likely to occur if, for example, initial discovery 
studies have low sample size and statistical power35,36. More reliable effect sizes can be estimated 
through validation in independent cohorts. 
 
Historically, to offset the high cost of commercial SNP arrays but retain statistical power GWAS 
were generally designed based on a staged strategy. That is, promising associations from the initial 
genome-wide analysis were followed up by targeted genotyping of independent  case-control 
series. The significantly reduced cost of arrays and the formation of international consortia have 
led to many analyses being solely based on the meta-analysis of genome-wide SNP data. While 
intrinsically attractive, the combination of data from different arrays can raise issues relating to 
varying quality of genotyping between array technologies as well as the density of SNP genotypes. 
Fortunately, the imputation of untyped genotypes using sequenced reference panels of individuals 
available through initiatives such as the 1000 Genomes Project37, UK10K consortium38 and 
haplotype reference consortium39, has facilitated the harmonisation of data generated  by 
different array formats. This has allowed SNP alleles with frequencies as low as 0.1% to be 
accurately imputed39 extending the utility of GWAS to decipher the allelic structure of cancer 
susceptibility. Of note, the role of structural variations, such as copy number variations (CNVs), is 
largely unappreciated, because existing arrays are not ideally formatted to capture them. 
 
[H1] Cancer risk loci identified 
Over the past decade, multiple GWAS have been reported for each of the major cancers in 
European populations, including breast40-42, prostate43-45, lung46-49, colorectal50-56, pancreatic57-60, 
gastric61,62, renal63-65 and bladder cancer66,67. For many of these, East Asian and African-American 
population specific risk loci have also been identified, reflecting differences in LD structure 
between ethnicities68. GWAS have also been reported for malignant melanoma69-71, ovarian 
cancer72-75, basal cell carcinoma76-79, glioma80-82, meningioma83, testicular germ cell tumour 
(TGCT)84-86, thyroid cancer87 and several of the haematological malignancies including the major B- 




cell tumours -  acute lymphocytic leukaemia  (ALL)88-91, chronic lymphocytic  leukaemia (CLL)92-94, 
multiple myeloma (MM)95-98, Hodgkin lymphoma (HL)99-101 follicular lymphoma102 and diffuse large 
B-cell lymphoma103. Additionally, common risk alleles have been identified through GWAS  for 
several paediatric solid cancers including Wilms tumour104 and neuroblastoma105. Each of these 
studies reported well-validated disease loci. Currently, more than 430 cancer associations at 262 
distinct genomic regions have been identified by GWAS (Supplementary Fig. 1, Supplementary 
Table 1). 
 
Breast and prostate cancer GWAS have so far yielded the greatest number of risk loci41,45. This high 
output is likely because of greater statistical power owing to the large sample size of the 
respective GWAS, each of which involved the genotyping of over 120,000 individuals41,45. For other 
cancers, differences in their heritability are likely to have influenced the performance of GWAS in 
identifying risk loci. For example, in CLL, which is strongly heritable and has an eight-fold familial 
RR106, GWAS have led to the identification of 43 risk loci, despite it being based on the analysis of 
only 6,200 patients and 17,598 controls92. In contrast, a GWAS analysis of 29,266 patients and 
56,450 controls has led to the discovery of only 18 risk loci for all lung cancer subtypes49, reflecting 
the importance of non-genetic risk factors in the aetiology of this cancer. 
 
 
[H1] Pleiotropy at cancer risk loci 
 
 
Most SNP associations identified to date have been cancer-specific, which is consistent with the 
epidemiological observations of most familial cancer risks1. However, approximately one third of 
SNPs map to genomic loci associated with multiple cancers. Classically pleiotropic loci would be 
those where the exact same association signal (and therefore presumed molecular mechanism) 
encompasses multiple cancers. A broader and perhaps more pragmatic definition encompasses 
cancer-specific “hotspots” with a presumed shared (but less direct) molecular mechanism, 
allowing  e.g.  for  cancer-  or  tissue-specific  enhancer  effects.  This  definition  of  pleiotropy  [G] 
enables the grouping of cancers or loci that can be instructive in our understanding of cancer by 
highlighting shared mechanisms or hallmarks, for example, telomere-related loci107 at  3q26.2 
(TERC), 5p15.33 (TERT), 10q24.33 (OBFC1) and 20q13.33 (RTEL1) are associated with risks  of 
multiple cancers107. In particular, the SNP rs2736100 at 5p15.33 (TERT) is associated with risk of 
many cancer types, including glioma81 as well as bladder108  and lung109  cancer. Similarly, the locus 
at 9p21.3 (CDKN2A-CDKN2B) has been found to influence glioma81, melanoma69, ALL110  and lung 




cancer111 risk, as well as naevi density112. For some loci the immediate cancer-specific mechanism 
of predisposition may not be shared, though ultimately they might converge on the same 
oncogenic mechanism. The SNP rs6983267 at chromosome 8q24.21 was found through scans of 
both prostate cancer113  and CRC114. However, this locus has also been shown to harbour risk SNPs 
for other cancers. These SNPs localise within distinct LD blocks and likely reflect tissue-specific 
effects on cancer risk64,66,75,81,93,99, through regulation of MYC (Fig. 3). 
 
Additional insights can be gained from the cancer types themselves implicated at “pleiotropic” 
loci. For example, 16q24.3 harbours multiple associations for skin cancers, including melanoma69, 
non-melanoma skin cancer115 and cutaneous squamous cell carcinoma116, which is likely indicative 
of a common, perhaps tissue-specific mechanism of action. Furthermore, additional  multiple- 
cancer regions are consistent with known familial co-clusters e.g. 19p13.11 and breast117 and 
ovarian74  cancer. For other regions containing multiple cancer associations, the shared genomic 
location is likely due to chance and the molecular basis of associations completely independent. In 
these cases there is no additional insight to be gained from collectively considering the multiple 
cancer and risk associations. Exploring  the nature of  pleiotropic loci will likely be  the focus of 
future work and lead to increased insight into cancer susceptibility and aetiology. 
 
[H1] Insights into cancer biology 
 
 
One of the anticipated deliverables from GWAS was that the identification of variants of genes in 
specific pathways would provide new insights into cancer biology. Few of the genes implicated by 
GWAS had previously been evaluated in targeted association studies, emphasizing that the 
candidate gene approach was hampered by a limited knowledge of tumour biology. Moreover, 
insights into new pathways of tumorigenesis for different cancer types have emerged; for 
example, the role of B-cell developmental and immune response genes (e.g. IKZF1, CEBPE, IRF4, 
IRF8,  GATA3  and  ARID5B)  as  key  determinants  of  the  risk  of  B-cell  tumours88-92,95,97-99,118-120. 
Similarly, GWAS implicated genes  involved  in  developmental  transcriptional  regulation, 
microtubule and chromosomal assembly, and components of the KIT-MAPK signalling pathway in 
TGCT oncogenesis121-124. 
 
Given the considerable difficulties in unambiguously identifying causative exposures for many 
cancers,  genetic  associations  have  the  potential  to  endorse  current  aetiological  hypotheses,  or 




suggest new ones that merit testing through gene- or environment-specific hypotheses. Examples 
of loci that demonstrate an effect on cancer risk mediated by lifestyle or environmental exposure 
include a SNP at 15q25 (CHRNA3-CHRNA5) locus that is indirectly associated with lung cancer risk 
through nicotine addiction46,125. The genotype at this locus influences the ability to quit smoking126 
and smokers carrying two copies of the CHRNA3-CHRNA5 risk allele smoke on average two more 
cigarettes per day (CPD) than those homozygous for non-risk alleles48. 
Other examples of genotype indirectly influencing cancer risk are provided by a SNP at 8p22 
(NAT2)modifying the effect of smoking on bladder cancer127 and the skin pigmentation loci that 
are associated with skin cancer69,76. Such data implies that heritable factors  may  well  have  a 
greater impact on cancer incidence than previously thought. 
 
Recently, researchers have suggested that “replicative” errors contribute substantially to cancer 
aetiology alongside environmental and heritable factors, inferred  from  observations  of  a 
correlation between total stem cell divisions and cancer incidence in various cancer types132, 133. 
However, such assertions warrant further scrutiny, as the relative contributions of factors 
havebeen calculated based on the assumption of independent effects, and have solely been based 
on high-penetrance inherited mutations, which contribute little to the population attributable risk 
[G] of a given cancer. All in all, it is likely that all of the posited components interact, with common 
GWAS susceptibility alleles also playing a role. 
 
[H1] Genetic risk in non-Europeans 
 
 
GWAS have been conducted in a number of non-European populations, either for cancers 
common in all populations (such as prostate, breast and colorectal cancer) or for those common in 
specific populations (e.g. hepatocellular carcinoma in East Asians). Approximately 56% of GWAS 
risk loci show association with only European populations, and 29% of GWAS risk loci show 
association with multiple populations, predominantly European, East Asian and African-American 
(Supplementary Table 1). Undoubtedly, cancer GWAS have been dominated by studies of 
European populations, so the proportion of GWAS risk loci associated with non-European 
populations is likely to increase as more studies in different populations are undertaken. 
Intriguingly, within certain risk loci exhibiting association with multiple populations, there may be 
population-specific association signals. For example for prostate cancer there appear to be several 
susceptibility  regions  at  8q24.21  with  differing  specificities  for  African  American,  Japanese 




American, Native Hawaiian, Latino and European American populations128. This might reflect 
population-specific disease mechanisms. 
 
Additionally, founder mutations arising in small populations can inform on cancer genetic risk. 
Examples outside of GWAS include bi-allelic NTHL1 mutations as a cause of recessive CRC 
discovered through sequencing Dutch families23, as well as APC p.Ile1307Lys (rs1801155) as a basis 
of low-penetrance susceptibility to CRC in individuals of Ashkenazi Jewish ancestry129. 
 
[H1] Common variation and heritable risk 
 
 
The loci identified through GWAS tend to exhibit dosage effects, with homozygous carriers of the 
risk allele having an excess risk approximately twice that of heterozygous carriers of the risk allele. 
This might partly reflect the fact that a log-additive model [G] has been used for the primary 
discovery, as even large GWAS will be underpowered to demonstrate significant deviation from 
this model130. 
 
Nearly all the cancer susceptibility loci identified to date are associated with modest increases in 
risk, with ORs generally less than 1.5. Exceptions to this are the SNPs at 9p21 (JAK2) for 
myeloproliferative neoplasms131, 12q21.32 (KITLG) for TGCT121,122  and 8q24.21 (CCDC26) for IDH- 
mutated glioma132, each of which are associated with a three-fold increased  risk of the respective 
cancer. These cancers are notable in having large familial  risks but  showing little evidence for 
Mendelian predisposition133-135. 
 
These GWAS data provide general  insights into  the  allelic  architecture  of  cancer  susceptibility. 
Even though the cancer risks associated with these SNPs are modest, the variants are common 
and therefore, each of them contributes to the risk of the respective cancer type in a large 
proportion of the population. The number of common variants each of which could explain more 
than 1% of inherited risk is very low. However, as the SNPs identified by GWAS have to pass a very 
stringent significance threshold, there are likely multiple SNPs with weak effect sizes that do not 
meet these  criteria but still  contribute  to  the  heritable risk of a given cancer. Quantifying the 
heritability explained by both known and potential susceptibility SNPs is therefore important to 
verify the aetiological basis of cancer and understand its genetic architecture. Calculating the 
proportion  of  phenotypic  variance  explained  by  a  large  number  of  SNPs  for  complex  human 
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diseases is a significant challenge. Methods such as Genome-wide Complex Trait  Analysis136 
(GCTA) [G] , which estimate the polygenic variance (i.e. heritability) ascribable to all GWAS SNPs 
simultaneously, have shown that common variation is likely to explain a high proportion of 
heritable risk of many cancers, with estimates of 10% for oestrogen receptor negative breast 
cancer137, 38% for prostate cancer137 and 17% for CRC138. More recent methods have attempted to 
improve GCTA by accounting for minor allele frequency, LD and genotype uncertainty. Such 
methods appear to produce higher estimates of heritability ascribed  to  common  genetic 
variation139, hence the contribution of polygenic inheritance to the heritable risk of cancer may 
currently be underestimated. 
 
Given the sample size of the GWAS that have been conducted, it is unlikely that there are many (or 
any) common  disease loci with minor allele frequencies (MAFs) >20% in European populations 
that have stronger effects than those already identified for the major cancer types. Many of the 
loci identified have ORs of 1.1 or less (Supplementary Table 1), and the statistical power of most 
studies will be too low to detect effects of this magnitude for uncommon alleles (i.e. MAF < 10%). 
As a consequence of the low statistical power as well as submaximal tagging the identification of 
risk variants conferring ORs of 1.05-1.1 will be problematic for all except the largest of studies140. 
 
[H1] Deciphering risk loci 
 
 
The underlying premise of GWAS is that an association reveals the effect of a highly correlated 
functional variant that is in LD with the tag SNP. Therefore, the genotyped SNP is not generally a 
strong candidate for causality, and elucidation of the causal variant poses a considerable 
challenge. Specifically, it is difficult to establish which of a set of closely linked variants that are in 
LD with each other  is  the  most functionally  relevant. While a  minority of  GWAS tag  SNPs  are 
directly functional, for example the 8q24.21 SNP rs6983267 for CRC141, most are likely in LD with 
the causal SNP. A key step in deciphering risk loci therefore is fine-mapping [G], which is aided by 
imputation of untyped genotypes142,143. Moreover, fine-mapping can also resolve association 
signals, for example the 8q24.21 association for glioma where the imputed SNP rs55705857 has 
been shown to be sufficient to explain two tag SNP signals previously thought  to  be 
independent132. 
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Many functional classes of genetic variation have been implicated as the basis of GWAS risk loci 
(Fig. 4). To date relatively few risk loci have been comprehensively studied. However, insights into 
the genetic and biological basis of cancer susceptibility mediated through common variation are 
emerging. 
 
A small number of the identified cancer GWAS loci directly impact on the amino acid sequence of 
the expressed protein. The mechanistic interpretation of such variants is presumed to be relatively 
simple, due to the implied direct relationship between genotype and function. Examples include 
BRCA2 p.Lys3326Ter (rs11571833) and CHEK2 p.Ile157Thr (rs17879961) for lung47 and breast 
cancer42. Similarly a direct relationship can be inferred for those affecting RNA processing such as 
the SNP in the 3’UTR (poly-A tail) of  TP53  (rs78378222)  associated  with  prostate  cancer  and 
glioma risk144,145, and those affecting splice sites such as the inhibitory splice isoform rs10069690 
variant at 5p15.33 (TERT), resulting in decreased telomerase activity146. However, it is possible that 
coding variants could have more subtle effects that do not necessarily involve disrupting protein 
function147, but instead involve tagging functional non-coding variants. 
 
Most risk  loci map to non-coding regions of the genome (e.g. gene introns or promoters and 
intergenic regions), which  is  perhaps  unsurprising  given  that  these  regions  comprise 
approximately 99% of the genome and the common, low–penetrance nature of these risk 
polymorphisms is  more compatible  with subtle,  regulatory effects. Indeed GWAS risk loci  have 
been demonstrated to map to genomic regions of cell-type specific active chromatin and show an 
over-representation of expression quantitative trait loci148, methylation quantitative trait  loci149 
and transcription factor (TF) binding150. Chromatin conformation  studies  have  helped  link 
regulatory regions, which SNPs identified by GWAS localise to, with their respective target 
genes151-153. Specifically, they have demonstrated that cis-regulatory  effects  mediated  by 
chromatin looping interactions between enhancers and promoter regions within topologically 
associated domains (TADs)154 are likely to be the functional basis of many GWAS signals. 
 
There have been significant efforts to understand the regulatory mechanisms perturbed at cancer 
risk loci. Such studies have been aided by statistical methodologies such as Summary-data-based 
Mendelian Randomization149 and initiatives such as the ENCODE155, Roadmap Epigenomics156 and 
BLUEPRINT epigenome157 consortiums which have generated publicly available maps of regulatory 
regions.   Furthermore,   network-based   approaches   have   yielded   insights   into   higher-order 




structures governing disease susceptibility. For example, binding of specific TFs can be enriched at 
risk loci. Such TFs are frequently mutated in tumours and have relevant biological activity158. 
 
The 8q24.21 region is one of the most intriguing and important loci to emerge from GWAS and is a 
good example of such regulatory mechanisms. The genomic interval at 128-130 megabases 
harbours multiple independent loci with distinct tumour specificities for CRC, glioma, CLL, MM, HL, 
and prostate, breast, and bladder cancers within the same TAD (Fig. 4). However, the region to 
which these cancer associations map is devoid of protein-coding transcripts. The 8q24.21 SNP 
rs6983267, which is associated with CRC and prostate cancer, resides in an evolutionarily 
conserved region. The two allelic variants of rs6983267 show  differential  binding  of  the 
transcription  factor  TCF7L2  to  an  enhancer  element  that  physically  interacts  with  the  MYC 
promoter, which is 300 kilobases telomeric to rs6983267141,159. The MYC oncogene is commonly 
amplified or overexpressed in many cancers. Recent Hi-C analysis [G] of this region has 
demonstrated a more complicated regulatory mechanism, implicating various lincRNAs that 
mediate effects at risk loci for example CCAT1, PCAT1 and CCDC26 for CRC, prostate cancer and 
glioma respectively152,153. While studies to fully elucidate the regulatory mechanisms underpinning 
the 8q24.21 locus and risks of various cancers are in their relative infancy, such endeavours will 
likely involve exploration of tissue-specific effects in appropriate model systems and CRISPR/Cas9- 
mediated disruption of candidate regulatory elements160. 
 
[H1] Subtype-specific associations 
 
 
Many cancers have distinct molecular profiles due to different aetiological pathways. The 
relationship between SNP genotype and tumour phenotype is becoming apparent for many cancer 
subtypes. In lung cancer, the 5p15.33 (TERT-CLPTM1L) and 3q28 (TP63) SNPs significantly 
influence lung cancer histology, and are principally associated with adenocarcinoma, while 13q12 
(BRCA2) and human leucocyte antigen (HLA) associations are specific for squamous lung cancer111. 
Similarly, many glioma risk loci are subtype-specific, such as associations at 5p15.33, 20q13.33 and 
7p11.2 for glioblastoma (GBM) and at 11q23.3 and 8q24.21 for non-GBM glioma82. Two of the 
most striking genotype-phenotype relationships identified to date are the 10q21.2 (ARID5B) ALL 
association, which seems to be highly selective for the subset of B-cell precursor ALL with 
hyperdiploidy (HD)88  and the CCND1 c.870G>A SNP which is specific for myeloma that has the 
(11;14)(q13;q32) translocation97. Presumably, such subtype-specific associations reflect particular 




mutational signalling contexts; thereby potentially providing insight into tumour development. 
Susceptibility alleles increasing cancer risk might confer a selective advantage and therefore be 
preferentially enriched in the given cancer relative to the non-risk allele. Evidence for such a 
phenomenon has been demonstrated recently for the SNP rs7090445 at 10q21.2. Here, the risk 
allele is preferentially retained in HD-ALL blasts, consistent with inherited genetic variation 
contributing  to  arrest  of  normal  lymphocyte  development,  and  this  facilitates  leukaemic  clonal 
expansion118. Similarly, the risk allele of the missense variant CDKN2A p.Ala148Thr (rs3731249), 
which increases ALL risk, has been shown to be preferentially selected during clonal evolution161. 
 
 
The recently proposed omnigenic model of complex disease susceptibility proposes that any gene 
with regulatory variants in disease relevant tissues will have an  effect  on  disease  risk.  In  this 
model, genes are defined as “core” if they have a specific role in disease aetiology and 
“peripheral” if their role is indirect. Given that there are more peripheral genes than core genes, 
and the range of effect sizes observed, a large fraction of the total genetic contribution to disease 
is thought to arise from peripheral genes that do not play direct roles in disease. Therefore, under 
this model, peripheral genes affect the regulation and function of core genes through networks, in 
a relatively subtle manner. This model is  based on our admittedly limited understanding of cancer 
and network biology and remains to be proven experimentally162. 
 
 
[H1] Clinical relevance 
 
 
As well as offering the prospect of risk stratification, cancer genetics provides for a better 
understanding of the developmental basis of cancer at a fundamental level. Such information can 
have direct clinical application in a number of contexts (Fig. 5). 
 
[H1] Drug discovery and repositioning 
 
 
Cancer genome sequencing studies provide evidence that regulatory regions and target genes 
implicated by GWAS are frequently the subject of somatic mutation, reflecting “driver activity”163- 
166.  Such  studies  can  aid  in  deciphering  risk  loci  and  offer  the  prospect  of  maximising  drug 
discovery efforts. Indeed, there are many successfully approved drugs for which GWAS has 
provided direct supporting genetic evidence167. This evidence has highlighted targets for drug 
development  and  identified  targets  for  potential  drug  repositioning168,169.  Although  not  in  the 




context of cancer, proof-of principle for this has been provided by the use of Ustekinumab, a 
monoclonal antibody that neutralizes the shared p40 subunit of IL-12 and IL-23170. GWAS 
identified the IL-23 signalling pathway as a risk factor for the development of psoriasis171 and the 
IL23R p.Arg381Gln (rs11209026) polymorphism was shown to afford protection from multiple 
inflammatory diseases172. Approved and promising therapies in cancer for which  GWAS 
associations exist include BCL2 inhibition in CLL92,173 and FGFR inhibition in breast cancer40,174. 
However, further work is required to identify target genes and aberrant biological pathways from 
GWAS associations and to define the germline-somatic continuum to maximise the potential of 
GWAS in drug discovery175. 
 
 
[H1] Stratified screening 
 
 
The possibility of identifying those at increased risk on the basis of their genotype is of  more 
immediate clinical relevance, since it will help to tailor prevention or screening strategies. The low 
level of risk associated with most cancer GWAS risk variants has been considered a barrier to the 
clinical application of these markers in cancer prevention. However, small effect sizes associated 
with individual SNPs do not necessarily preclude clinical utility. As demonstrated for CRC as well as 
breast and prostate cancer, the combined effect of multiple risk SNPs has the potential to achieve 
a degree of risk discrimination that is useful for population-based prevention and screening 
programmes. For example, a polygenic risk score (PRS) based on the 37 known risk variants for 
CRC indicates that individuals with the top 10% highest scores will have a 1.8-fold increased risk of 
CRC and those within the top 1% will have a 2.9-fold increased risk of CRC when compared with 
the  population  median  (Fig.  6)138,176.  Making  use  of  a  PRS  has  the  potential  to  optimise  the 
efficiency of population-based screening programmes for the early detection of  CRC,  prostate 
cancer and breast cancer138,177. Furthermore, the observed level of risk discrimination from PRS 
may be informative in formulating and delivering chemoprevention strategies. Use of PRS has also 
recently been shown to provide informative cancer risk stratification in the context of Mendelian 
cancer susceptibility, notably for BRCA1 and BRCA2 mutation carriers178,179. 
 
[H1] Informing prevention 
 
 
Mendelian Randomisation (MR) analysis enables identification of non-genetic risk factors and 
possible chemoprevention agents by use of GWAS data [BOX 2]. For example, by using genetic 




markers as proxies (i.e. genetic instruments) for hyperlipidaemia, a causal relationship between 
hypercholesterolemia and CRC has been demonstrated180. Furthermore, a genetic risk score 
comprising SNPs which lower 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) expression, and 
therefore mimicking the effects of statin therapy to reduce cholesterol levels, was associated with 
reduced CRC risk180. Such data provides support for additional clinical benefit from statins aside 
from their primary use in the context of coronary heart disease. A significant challenge when 
conducting MR analysis is to ensure validity of genetic instruments by excluding pleiotropy [BOX 
2]. Whilst methods have been developed to quantify pleiotropy in such studies, these  have 
received scrutiny in the proposed omnigenic model that proposes the concept of “network 
pleiotropy”, i.e. a single variant may affect multiple traits because those traits  are  mediated 
through the same regulatory networks in the same cell types rather than because the traits are 
causally related162. Such “network pleiotropy” may not be readily detected in traditional MR-based 
analyses. 
 
[H1] Informing treatment 
 
 
As a potential prognostic factor, the concept of germline variation imparting inter-individual 
variability in tumour development and progression is receiving increasing attention with examples 
in many cancer types181-185. Genetic variation has been linked to treatment response in CLL, and 
lung and breast cancer, whereby chemotherapies that are CYP3A substrates such as 
cyclophosphamide, taxanes and mitoxantrone, may be suboptimal for CYP3A7*1C carriers186. 
Furthermore,  GWAS  has  been  successful  in  identifying  individuals  at  risk  of  treatment  related 
toxicity such as anthracycline-induced cardiotoxicity187 and radiotherapy  induced  tissue 
damage188. Hence GWAS offers an opportunity to realize the vision of personalized medicine by 
identifying common genetic variation affecting drug efficacy and drug-induced toxicity. This can 
improve therapeutic decision making, enabling the possibility of patient-tailored drug selection. 
 
[H1] Conclusions and future challenges 
 
 
GWAS have demonstrated that much of the heritable risk for most common cancers is polygenic. 
Hence the architecture of inherited genetic susceptibility to cancer is defined by a montage of 
predisposition alleles with different levels of risk and prevalence in the  population.  With  the 
notable exception of breast and prostate cancer, the currently identified loci explain only a small 
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proportion of the familial risk of many cancers. Many GWAS have long tails of low OR associations, 
suggesting that larger studies should identify many more new susceptibility loci. Although rare 
recurrent disease-causing variants may not make a substantial contribution to the heritable risk of 
cancer, this class of risk variants have probably been under-discovered. Hence subjecting GWAS 
datasets to imputation using recently developed reference panels to recover sub-polymorphic risk 
alleles (i.e. risk allele frequency <1%) is likely to be a profitable avenue of research. 
 
The loci identified through GWAS have greatly expanded the existing repertoire of genes that 
influence cancer risk. Determining the functional consequences of GWAS data is however likely to 
continue to be challenging, but is required to fully exploit GWAS in order to gain a greater 
understanding of cancer biology and suggest potential targets for therapeutic and preventive 
strategies. Advances in model systems and strategies such as saturating mutagenesis of risk loci 
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Box 1: Genome-wide significance threshold 
 
While historically other thresholds have been proposed40,191, the commonly accepted threshold 
for genome-wide significance is P<5x10-8, i.e. a Bonferroni correction at the 5% significance level 
for 1,000,000 independent tests. The first published mention of this  was  through  simulation 
studies by Risch and Merikangas in 1996192, assuming 100,000 genes with five bi-allelic SNPs per 
gene, testing for each allele independently. This has proven remarkably close to empirical 
estimates such as 150 per 500 Kb from the International HapMap Consortium in 2005, which leads 
to a two-sided significance threshold of 5.5x10-8 when extending to the whole genome33. 
More recently this threshold has remained in place for sequencing studies or those making use of 
whole-genome imputation of >10 million common variants, under the assumption that LD 
between SNPs approximates to ~1 million independent tests. 
Box 2: The principles of Mendelian randomization 
 
In observational studies, establishing a causal relationship between two associated variables may 
not always be possible. Furthermore, unmeasured factors (confounders) may influence both 
variables and thus explain the observed association. Mendelian randomization (MR) is a technique 
aimed at unbiased assessment of causal effects and estimation of their magnitude. 
MR uses genetic markers known to be associated with a potential risk factor in the assessment of 
its effect on another trait or disease193. These markers, termed instrumental variables (IVs), rely on 
a number of assumptions, namely that the IVs are solely associated with the trait or disease (i.e. 
absence of pleiotropy), and that the IVs are independent of confounders. This methodology can 
allow for causality to be assessed without the influence of confounding factors. 
With the development of large genomic datasets and establishment of robust IVs in the form of 
genetic risk variants, MR offers the ability to identify non-genetic risk  factors194, 
chemopreventative agents180  and perform safety analysis of therapies195. 







Figure 1: Genetic architecture of cancer risk. This graph depicts the low relative risks (RRs) 
associated with common, low-penetrance genetic variants, such as single-nucleotide 
polymorphisms identified in genome-wide association studies; moderate RRs associated with 
uncommon, moderate-penetrance genetic variants such as ATM and CHEK2; and a higher RR 
associated with rare, high-penetrance genetic variants, such as pathogenic  mutations in  BRCA1 
and BRCA2 associated with hereditary breast and ovarian cancer. 





Figure 2: GWAS design. DNA from patients and controls are genotyped using commercially 
available genome platforms that assess for common genetic variations in the form of single 
nucleotide polymorphisms (SNPs) across the entire human genome. Data are reviewed to ensure 
appropriate genotyping quality. Genome  imputation allows  for recovery  of  untyped SNPs. 
Association test statistics are generated to identify genetic risk loci. Where more than one dataset 
is available, a meta-analysis is conducted to increase study power. Replication in appropriate study 
populations may also be performed to validate associations. 





Figure 3: Regulatory interactions at the pleiotropic 8q24.21 risk locus. Plotted region is 
chr8:127,000,000-130,700,000 (build 37). (a) Looping interactions overlapping cancer association 
signals; (b) Relative location of cancer GWAS signals (Supplementary Table 1); (c) Epigenetic marks 
– peaks represent histone modifications and indicate DNA with the potential for influencing gene 
expression of neighbouring genes and through looping interactions, distant genes; (d) Refseq gene 
annotation (build 37). Abbreviations: PrC, prostate cancer; MM, multiple myeloma; CLL, chronic 
lymphocytic leukaemia; BrC, breast cancer; CRC, colorectal cancer; BlC, bladder cancer; FL, 
follicular lymphoma; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma;  EC, 
endometrial carcinoma; OC, ovarian cancer; PaC, pancreatic cancer. 





Figure 4: Potential molecular mechanisms of GWAS risk SNPs. (a) The A>G polymorphism is 
affecting gene transcription through altering transcription factor (TF) binding through looping 
promoter-enhancer-complex interaction; (b) Affecting mRNA processing (e.g. splicing, poly- 
adenylation). The A>G polymorphism depicted occurs at an intron splice site and results in intron 
retention; (c) The A>G polymorphism leads to generation of a novel microRNA binding site on a 
lincRNA; (d) The A>G polymorphism affects the protein sequence by causing amino acid 
substitution of tyrosine to cytosine) 







Figure 5: The clinical application of GWAS. Overview of different applications of cancer GWAS, as 
described in the review. As well as enhancing our knowledge of cancer biology, GWAS can inform 
on aetiological risk factors for cancer. Through risk modelling, data from GWAS can assist in 
identifying individuals at increased risk of developing cancer and therefore help prevent cancer 
and improve early detection  through screening. Genes and pathways identified through  GWAS 
may inform drug discovery and repositioning as well as guide clinicians and patients on cancer 
prognosis and treatment related complications. 
 
 







Figure 6: Population distribution of polygenic risk score for CRC ordered by RR. Based on the 
known 37 risk SNPs. Vertical red lines (left to right) correspond to 1%, 10%, 50%, 90%, and 99% 
centile, respectively. Individuals within the top 10% of genetic risk have a 1.8-fold increased risk of 
CRC and those within the top 1% (i.e. 27–54 risk alleles) have a 2.9-fold increased risk of CRC when 
compared with the population median. 
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Relative Risk (RR) – ratio of disease occurrence in one group versus another (e.g. cancer risk in 
patient relatives compared with the general population). The RR estimate associated with 
common risk alleles identified through GWAS is usually a per-allele RR (co-dominant log-additive 
genetic model). 
Mendelian predisposition – This occurs when germline mutation in a single gene (e.g. cancer 
susceptibility gene) is sufficient to cause cancer in a majority of patients (e.g. female carriers of 
BRCA1 mutations have ~80% lifetime risk of developing breast cancer). These mutations can be 
dominant or recessive, caused by mono-allelic and bi-allelic mutations respectively. 
Cancer Susceptibility Gene (CSG) – genes in which inherited  mutations  (commonly  high- 
penetrance) predispose to cancer. 
Penetrance – proportion of individuals carrying a particular allele (e.g. in a cancer susceptibility 
gene) that go on to develop cancer. High-penetrance mutations confer a  high  risk  of  causing 
cancer, whereas low-penetrance polymorphisms confer a small risk. 
Linkage Disequilibrium (LD) – non-random association of alleles at different sites in a given 
population. Alleles in high LD are those where their shared frequency combinations are greater 
than would be expected if they were inherited independently. LD can be affected by factors such 
as natural selection and genetic drift, as well as rates of mutation and recombination. 
Heritability – estimate of the proportion of variation in a trait in a given population that is due to 
genetic variation. In particular, narrow-sense heritability (h2) is the proportion of variance in a trait 
due to additive genetic factors, whereas broad-sense heritability (H2) is the proportion of variance 
in a trait due to all genetic factors (e.g. including dominance, gene-gene interactions). 
 
Genome-wide complex trait analysis (GCTA) - computational method by which the narrow-sense 
heritability of a trait can be estimated through case-control GWAS genotypes and estimates of 
trait incidence. 
Fine-mapping – process of refining GWAS association signals and prioritising likely causative 
variants e.g. through in silico annotations of putative functional effect. 
Hi-C analysis – a form of chromosome conformation capture, in which cross-linked DNA fragments 
are sequenced in order to infer the three-dimensional structure of the genome and identify 
potential regulatory interactions. 
Effect size – quantitative measurement statistic of the strength of an association between two 
variables e.g. SNP genotype and cancer risk. 
Risk allele frequency – frequency of risk allele (B) in a given population at a bi-allelic site with non- 
risk allele (A), derived from genotype counts through formula (2xBB+AB)/(2x(AA+AB+BB)) 
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Odds ratio – odds that an outcome will occur given a particular exposure  compared  to  the 
absence of that exposure e.g. comparing variant site allele frequency in cancer patients and 
controls. 
Population attributable risk – number of cases of disease among exposed individuals that can be 
attributed to that exposure (e.g. carriers of a particular risk SNP). 
Pleiotropy – occurs when a risk locus is associated with multiple phenotypic traits. In some cases 
the same variant is presumed to influence multiple traits, while in other cases different traits map 
to distinct locations within the risk locus. 
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